Baricitinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Baricitinib
- Baricitinib: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
Baricitinib: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
Baricitinib is a JAK1/JAK2 inhibitor originally used to treat rheumatoid arthritis. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, a rare developmental malformation syndrome, but no clinical trials and no publications currently support this prediction. It rests on a model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, baricitinib is a Janus kinase (JAK1/JAK2) inhibitor. Its efficacy in rheumatoid arthritis is established, where it dampens inflammatory cytokine signaling through the JAK-STAT pathway.
For the predicted indication, no plausible JAK-inhibition rationale is evident. Colobomatous microphthalmia-rhizomelic dysplasia syndrome is a rare developmental malformation syndrome that is likely driven by structural or developmental genetics rather than inflammatory signaling. The very high score (0.999) is a knowledge-graph prediction only, and it should be treated with caution.
Other predictions in the same list include indolent plasma cell myeloma, plasma cell myeloma and myeloid leukemia. They have a more credible link through IL-6/JAK/STAT3 signaling, but their supporting evidence is also limited (see the conclusion).
Clinical Trial Evidence
Currently no related clinical trials registered for the predicted indication.
Literature Evidence
Currently no related literature available for the predicted indication.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15505P | OLUMIANT FILM-COATED TABLET 4MG | Tablet, film coated | Not stated in the data compiled |
| SIN15504P | OLUMIANT FILM-COATED TABLET 2MG | Tablet, film coated | Not stated in the data compiled |
Safety Considerations
- Drug Interactions: The interaction screening completed and returned 100 interactions in total. The main ones listed here are:
- Major: systemic and ophthalmic corticosteroids (hydrocortisone, triamcinolone, betamethasone, budesonide, dexamethasone, prednisolone, prednisone), deferiprone, and radiopharmaceuticals or radioimmunotherapies (ibritumomab tiuxetan, iobenguane I-131, tositumomab I-131)
- Moderate: morphine (including liposomal), opium, acetylsalicylic acid, nitisinone
- Minor: zinc salts (acetate, gluconate, sulfate)
- Other note: For heparin cofactor 2 deficiency (a lower-ranked prediction), the rationale notes that baricitinib carries a thrombosis warning, which would be unfavorable there.
Please refer to the package insert for warnings and contraindications, as this information was not available in the data compiled.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for colobomatous microphthalmia-rhizomelic dysplasia syndrome is supported only by a model score, with no trials, no literature and no evident biological link to JAK-STAT signaling. The evidence level is L5. Of the other predictions, plasma cell myeloma and myeloid leukemia have only indirect evidence (a COVID-19 case report and a graft-versus-host disease prevention trial, respectively), and are better viewed as research questions than as ready candidates.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are currently missing and block safety screening
- Detailed mechanism of action data (MOA)
- A biological rationale linking JAK1/2 inhibition to the predicted syndrome (for example, preclinical or genetic evidence)
- Approved indication text for the Singapore registrations
- If the team wants to pursue this drug further, a re-prioritisation toward candidates with a plausible mechanism (such as plasma cell myeloma) and targeted trial or literature searches for them
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.